P14.66 TTFields dose distribution and tumor growth patterns confirm clinical activity of TTFields: MRI analysis of the randomized phase 3 EF-14 trial

BACKGROUND: The randomized phase 3 EF-14 trial showed that the addition of tumor treating fields (TTFields) to temozolomide (TMZ) treatment improved survival in newly diagnosed glioblastoma patients over TMZ alone. As TTFields delivery is designed to optimize dose at the tumor bed, we hypothesized t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Kebir, S, Ballo, M T, Jeyapalan, S, Toms, S A, Hottinger, A, Pollom, E, Glas, M
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Poster Presentations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795946/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.301
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky